Analysts' ratings for Danaher DHR over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 8 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 7 | 2 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $293.29, a high estimate of $315.00, and a low estimate of $265.00. Highlighting a 0.58% decrease, the current average has fallen from the previous average price target of $295.00.
Investigating Analyst Ratings: An Elaborate Study
The perception of Danaher by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sung Ji Nam | Scotiabank | Announces | Sector Perform | $265.00 | - |
| Derik De Bruin | B of A Securities | Maintains | Buy | $290.00 | $290.00 |
| Doug Schenkel | Wolfe Research | Announces | Outperform | $285.00 | - |
| Conor McNamara | RBC Capital | Lowers | Outperform | $311.00 | $333.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $315.00 | $310.00 |
| Paul Knight | Keybanc | Raises | Overweight | $310.00 | $290.00 |
| Jacob Johnson | Stephens & Co. | Maintains | Overweight | $315.00 | $315.00 |
| Daniel Arias | Stifel | Raises | Hold | $265.00 | $250.00 |
| Dan Leonard | UBS | Lowers | Buy | $305.00 | $309.00 |
| Andrew Cooper | Raymond James | Lowers | Outperform | $300.00 | $310.00 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $275.00 | $285.00 |
| Catherine Schulte | Baird | Lowers | Outperform | $277.00 | $278.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $278.00 | $275.00 |
| Jacob Johnson | Stephens & Co. | Announces | Overweight | $315.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Danaher. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Danaher's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Danaher's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Danaher analyst ratings.
Delving into Danaher's Background
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Breaking Down Danaher's Financial Performance
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Danaher's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 3.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 14.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA excels beyond industry benchmarks, reaching 1.03%. This signifies efficient management of assets and strong financial health.
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
